摘要
20世纪90年代以来,手性药物的研究与开发成为世界新药开发的战略方向和热点领域。这是因为生物体和生命活动中的手性识别过程导致手性药物对映体相互作用的药效学和药动学差异,手性药物的开发符合人体与药物相互作用中高度立体选择性的特点。1992年,美国FDA规定,所有在美国上市的新混旋药物的生产商必须提供报告,据报道,药物中对映体的药效作用使混旋体新药的开发成本翻了一番,开发周期极大延长。但是,如果申请的新药是纯光学活性剂,工作量和成本将极大降低,这就促使人们积极选择和开发手性药物。不对称催化反应的研究成功地为手性药物工业注入了新的强大的技术动力,合成并发现了适合不同类型不对称反应的酶。
Since the 1990 s,research and development of chiral drugs has become the strategic direction and hot area of new drug development in the world.This is because the chiral recognition process in living organisms and life activities leads to pharmacodynamic and pharmacokinetic differences in the interaction of chiral drug enantiomers.The development of chiral drugs is in line with the highly stereoselective nature of human-drug interactions.Features;In 1992,the US FDA required that all manufacturers of new mixed drugs marketed in the United States must provide reports.It is reported that the enantiomeric effect of the drug doubled the development cost of new mixed drugs.The development cycle has been greatly extended.However,if the applied new drug is a pure optically active agent,the workload and cost will be greatly reduced,which motivates people to actively select and develop chiral drugs.The research on asymmetric catalytic reactions has successfully injected a new powerful technical impetus into the chiral drug industry,and synthesized and discovered enzymes suitable for different types of asymmetric reactions.
出处
《化工设计通讯》
CAS
2019年第12期218-219,共2页
Chemical Engineering Design Communications
关键词
不对称催化反应
医药合成
开发应用
asymmetric catalytic reaction
pharmaceutical synthesis
development and application
